Marianna Riekkinen is affiliated with multiple esteemed institutions, including the Meilahti Vaccine Research Center (MeVac) at the University of Helsinki and Helsinki University Hospital. She is also associated with the Department of Infectious Diseases at the Inflammation Center of Helsinki University Hospital. In addition, she contributes to research at the Human Microbiome Research Unit at the University of Helsinki and offers her expertise at the Travel Clinic, Aava Medical Center, in Helsinki, Finland. Her work is primarily focused on infectious diseases, contributing significantly to the understanding and management of COVID-19.
Research Contributions
Marianna Riekkinen has made notable contributions to the study of infectious diseases, particularly in the context of the COVID-19 pandemic. Her research includes examining the kinetics of neutralizing antibodies in COVID-19 patients using various clinical isolates in microneutralization assays. She has also explored the reduced neutralization capabilities of convalescent sera against emerging variants of SARS-CoV-2, such as the B.1.351 variant. Her work is crucial in understanding the immune responses to different strains of the virus, contributing valuable insights into vaccine development and therapeutic strategies.
Aliases
Marianna Riekkinen is also known by the alias "Maria Riekkinen," which may appear in some of her publications or professional references.
